{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:24:56Z","timestamp":1790889896972,"version":"4.1.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi241505-4\"><jats:title>Importance<\/jats:title><jats:p>The ability to predict the onset of mild cognitive impairment (MCI) and Alzheimer dementia (AD) could allow older adults and clinicians to make informed decisions about dementia care.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241505-5\"><jats:title>Objective<\/jats:title><jats:p>To assess whether the age at onset of MCI and AD can be predicted using a statistical modeling approach.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241505-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This prognostic study used data from 2 aging and dementia cohort studies\u2014the Australian Imaging, Biomarker and Lifestyle (AIBL) study and the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)\u2014for model development and validation of the Florey Dementia Index (FDI), a tool used to predict the age at onset of MCI and AD in older adults. Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer (A4) study were used for a simulated trial. Data were collected from 1665 AIBL participants, 2029 ADNI participants, and 93 A4 participants from October 1, 2004, to March 1, 2023. The data analysis was conducted between January and August 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241505-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Predicted age at onset compared with clinically observed age at onset.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241505-8\"><jats:title>Results<\/jats:title><jats:p>Among the 1665 AIBL participants (741 [44.5%] female) and 2029 ADNI participants (925 [45.6%] female), the mean (SD) age at first evaluation was 71.8 (7.1) years and 74.5 (6.7) years, respectively.  The FDI achieved mean absolute errors of 2.78 (95% CI, 2.63-2.93) years for predicting MCI onset and 1.48 (95% CI, 1.32-1.65) years for predicting AD onset. In the simulated trial with 93 A4 participants (48 [51.6%] female; mean [SD] age at baseline, 73.4 [5.1] years), the FDI achieved mean absolute errors of 1.57 (95% CI, 1.41-1.71) years for predicting MCI onset and 0.70 (95% CI, 0.53-0.88) years for predicting AD onset.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241505-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this prognostic study, the FDI was developed and validated to predict the onset age of MCI and AD. This tool may be useful in organizing health care for older adults with cognitive decline or dementia and in the future may help prioritize patients for the use of disease-modifying monoclonal antibody drugs.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.53756","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T16:00:58Z","timestamp":1736352058000},"page":"e2453756","source":"Crossref","is-referenced-by-count":9,"title":["Development and Validation of a Tool to Predict Onset of Mild Cognitive Impairment and Alzheimer Dementia"],"prefix":"10.1001","volume":"8","author":[{"given":"Chenyin","family":"Chu","sequence":"first","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia"},{"name":"Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia"},{"name":"Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Wang","sequence":"additional","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia"},{"name":"Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fowler","sequence":"additional","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Zisis","sequence":"additional","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Doecke","sequence":"additional","affiliation":[{"name":"Australian e-Health Research Centre, Health and Biosecurity, Commonwealth Scientific and Industrial Research Organisation, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Goudey","sequence":"additional","affiliation":[{"name":"Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia"},{"name":"The ARC Training Centre in Cognitive Computing for Medical Technologies, University of Melbourne, Carlton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Jin","sequence":"additional","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia"},{"name":"Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Pan","sequence":"additional","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia"},{"name":"Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"AIBL Research Group and the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Weiner","sequence":"additional","affiliation":[{"name":"for the AIBL Research Group and the Alzheimer\u2019s Disease Neuroimaging Initiative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Aisen","sequence":"additional","affiliation":[{"name":"for the AIBL Research Group and the Alzheimer\u2019s Disease Neuroimaging Initiative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Petersen","sequence":"additional","affiliation":[{"name":"for the AIBL Research Group and the Alzheimer\u2019s Disease Neuroimaging Initiative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel","family":"Beckett","sequence":"additional","affiliation":[{"name":"for the AIBL Research Group and the Alzheimer\u2019s Disease Neuroimaging Initiative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Perrin","sequence":"additional","affiliation":[{"name":"for the AIBL Research Group and the Alzheimer\u2019s Disease Neuroimaging Initiative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur W.","family":"Toga","sequence":"additional","affiliation":[{"name":"for the AIBL Research Group and the Alzheimer\u2019s Disease Neuroimaging Initiative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Saykin","sequence":"additional","affiliation":[{"name":"for the AIBL Research Group and the Alzheimer\u2019s Disease Neuroimaging Initiative"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"issue":"1","key":"zoi241505r1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JAD-230938","article-title":"How can we use mathematical modeling of amyloid-\u00df in Alzheimer\u2019s disease research and clinical practices?","volume":"97","author":"Chu","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"zoi241505r2","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer\u2019s disease.","volume":"1","author":"Masters","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"zoi241505r3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13195-024-01540-6","article-title":"Understanding machine learning applications in dementia research and clinical practice: a review for biomedical scientists and clinicians.","volume":"16","author":"Wang","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"zoi241505r4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi241505r5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease.","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi241505r6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease.","volume":"11","author":"Blennow","year":"2015","journal-title":"Alzheimers Dement"},{"key":"zoi241505r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102834","article-title":"Development and validation of the Florey Dementia Risk Score web-based tool to screen for Alzheimer\u2019s disease in primary care.","volume":"76","author":"Pan","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"zoi241505r8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3233\/ADR-210005","article-title":"Fifteen years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer\u2019s disease.","volume":"5","author":"Fowler","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"issue":"7","key":"zoi241505r9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jalz.2015.04.005","article-title":"Impact of the Alzheimer\u2019s disease neuroimaging initiative, 2004 to 2014.","volume":"11","author":"Weiner","year":"2015","journal-title":"Alzheimers Dement"},{"key":"zoi241505r12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073538","article-title":"Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA).","volume":"381","author":"Snell","year":"2023","journal-title":"BMJ"},{"issue":"6","key":"zoi241505r13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1006\/jbin.2002.1038","article-title":"Modeling medical prognosis: survival analysis techniques.","volume":"34","author":"Ohno-Machado","year":"2001","journal-title":"J Biomed Inform"},{"key":"zoi241505r14","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.631770","article-title":"The impact of disease comorbidities in Alzheimer\u2019s disease.","volume":"13","author":"Santiago","year":"2021","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"zoi241505r15","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s44197-024-00266-w","article-title":"Elucidating the link between anxiety\/depression and Alzheimer\u2019s dementia in the Australian Imaging Biomarkers and Lifestyle (AIBL) study.","volume":"14","author":"Ma","year":"2024","journal-title":"J Epidemiol Glob Health"},{"issue":"2","key":"zoi241505r16","article-title":"Exploring the link between comorbidities and Alzheimer\u2019s dementia in the Australian Imaging, Biomarker & Lifestyle (AIBL) study.","volume":"16","author":"Nguyen","year":"2024","journal-title":"Alzheimers Dement (Amst)"},{"issue":"11","key":"zoi241505r17","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1175\/1520-0477(1982)063<1309:SCOTEO>2.0.CO;2","article-title":"Some comments on the evaluation of model performance.","volume":"63","author":"Willmott","year":"1982","journal-title":"Bull Am Meteorol Soc"},{"issue":"8","key":"zoi241505r22","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","article-title":"Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer\u2019s research consortium study.","volume":"65","author":"O\u2019Bryant","year":"2008","journal-title":"Arch Neurol"},{"key":"zoi241505r23","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.1021792","article-title":"Sum of boxes of the clinical dementia rating scale highly predicts conversion or reversion in predementia stages.","volume":"14","author":"Tzeng","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"zoi241505r25","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200055","article-title":"Neuropathology-independent association between APOE genotype and cognitive decline rate in the normal aging-early Alzheimer continuum.","volume":"9","author":"Qian","year":"2023","journal-title":"Neurol Genet"},{"issue":"5","key":"zoi241505r26","first-page":"S281","article-title":"Early diagnosis of Alzheimer\u2019s disease: clinical and economic benefits.","volume":"51","author":"Leifer","year":"2003","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"zoi241505r27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1017\/S1355617708080375","article-title":"Trajectory of mild cognitive impairment onset.","volume":"14","author":"Howieson","year":"2008","journal-title":"J Int Neuropsychol Soc"},{"issue":"12","key":"zoi241505r28","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/alz.12351","article-title":"The \u201ccognitive clock\u201d: a novel indicator of brain health.","volume":"17","author":"Boyle","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"8","key":"zoi241505r29","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/alz.13004","article-title":"Predicting age at Alzheimer\u2019s dementia onset with the cognitive clock.","volume":"19","author":"Yu","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"7","key":"zoi241505r30","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/13854046.2015.1119312","article-title":"How do scores on the ADAS-Cog, MMSE, and CDR-SOB correspond?","volume":"29","author":"Balsis","year":"2015","journal-title":"Clin Neuropsychol"},{"key":"zoi241505r31","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.101983","article-title":"Interactive effect of age and APOE-e4 allele load on white matter myelin content in cognitively normal middle-aged subjects.","volume":"24","author":"Operto","year":"2019","journal-title":"Neuroimage Clin"},{"issue":"9","key":"zoi241505r32","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0895-4356(03)00207-5","article-title":"External validation is necessary in prediction research: a clinical example.","volume":"56","author":"Bleeker","year":"2003","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"zoi241505r33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/alz.12797","article-title":"Increasing participant diversity in AD research: plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer\u2019s Disease Neuroimaging Initiative 4.","volume":"19","author":"Weiner","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi241505r34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3233\/JAD-240241","article-title":"A comparison of an Australian observational longitudinal Alzheimer\u2019s disease cohort to community-based Australian data.","volume":"101","author":"Huynh","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"zoi241505r35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13195-024-01567-9","article-title":"Reliability of the assessment of the clinical dementia rating scale from the analysis of medical records in comparison with the reference method.","volume":"16","author":"Dauphinot","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"zoi241505r36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.33786","article-title":"Evaluation of the Electronic Clinical Dementia Rating for dementia screening.","volume":"6","author":"Nosheny","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi241505r20","author":"Therneau","year":"2015"},{"key":"zoi241505r21","author":"Kassambara","year":"2016"},{"key":"zoi241505r10","unstructured":"Alzheimer Disease Neuroimaging Initiative. Accessed November 14, 2024. https:\/\/adni.loni.usc.edu\/"},{"key":"zoi241505r11","unstructured":"Alzheimer\u2019s Clinical Trials Consortium. Anti-Amyloid Treatment in Asymptomatic Alzheimer\u2019s (A4) Study and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study. Accessed November 14, 2024. https:\/\/www.a4studydata.org\/"},{"key":"zoi241505r18","unstructured":"Sperling? RA, Aisen? PS. Anti-Amyloid Treatment in Asymptomatic Alzheimer\u2019s Disease (A4) Open-Label Extension Study. Accessed November 14, 2024. https:\/\/reporter.nih.gov\/project-details\/10554282"},{"key":"zoi241505r19","unstructured":"Pinheiro? J, Bates? D, DebRoy? S, Sarkar? D. R Core Team. nlme: linear and nonlinear mixed effects models. R package version 3.1-137. 2018. Accessed November 28, 2024. http:\/\/CRAN.R-project.org\/package=nlme"},{"key":"zoi241505r24","unstructured":"Github. Demo Video. Accessed November 14, 2024. https:\/\/github.com\/auccy\/video"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2828798\/chu_2025_oi_241505_1735232482.85893.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T16:01:06Z","timestamp":1736352066000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2828798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.53756","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}